More than one-third of patients with atrial fibrillation who are have a moderate to high risk for stroke are being treated with aspirin, even though it is well known that blood thinners provide more protection.
More than one-third of patients with atrial fibrillation (AF) who are have a moderate to high risk for stroke are being treated with aspirin, even though it is well known that blood thinners are more effective, according to a new study published online in Journal of the American College of Cardiology. The study found that approximately 40% of more than 200,000 patients with AF who were being treated by cardiovascular specialists were receiving aspirin alone.
The study’s authors, led by Jonathan C. Hsu, MD, MAS, of the University of California San Diego School of Medicine, noted that the incidence of stroke is up to seven times greater among AF patients than in those without the condition because AF causes abnormal contractions in the heart’s upper chambers that make formation of blood clots more likely.
“Giving aspirin alone to this population may not be the best treatment because it is either minimally effective or not effective at all and still comes with risks, such as intracranial hemorrhage,” Hsu said in a statement. “Our study results show a gap in the appropriate treatment of AF patients at risk for stroke.”
The findings also reveal a critical need for cardiology specialists to adhere to the standardized recommendations regarding the use of oral anticoagulants instead of aspirin.
The study followed 2 groups of AF outpatients who had at intermediate to high risk of stroke and who were enrolled in the American College of Cardiology PINNACLE registry between 2008 and 2012. The authors used statistical analyses and models, adjusting for patient and real-world cardiology practice characteristics, to examine the predictors and prevalence of receiving aspirin alone versus oral anticoagulation prescriptions in AF patients at risk for stroke. They found that conditions related to coronary artery disease including hypertension, high cholesterol, and prior heart attack were associated with more frequent prescription of aspirin only. Male sex, a higher body mass index, a prior stroke, and congestive heart failure were associated with more frequent prescription of oral anticoagulants.
The researchers expressed concern about the high rate of aspirin-only prescriptions for AF patients with coronary artery disease uncovered in their study.
“It appears patients with more risk factors for having a stroke with AF are less likely to get the proper treatment, which is oral blood thinners,” said Hsu.
Approximately one-third of the AF patients who didn’t have significant coronary artery disease were prescribed both an oral anticoagulant and aspirin, putting them at higher risk for bleeding without any evidence that it would benefit them, the investigators said.
The biggest reason for underuse of appropriate oral anticoagulation therapy in AF patients may be physicians’ concern about bleeding, the authors surmise. More studies evaluating cardiovascular outcomes in AF patients prescribed aspirin only versus oral blood thinners, or a combination of the 2, are needed.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More